Clinical Trial

Probiotics Against Erythropoietin Resistance in Chronic Kidney Disease Patients.

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated December 22, 2025 (before its estimated March 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
The goal of this clinical trial is to assess whether probiotic supplementation can improve the hematological response of CKD patients to erythropoietin therapy and prevent or reduce erythropoietin resistance. The main questions it aims to answer are: Can probiotic be used as an adjuvant strategy in anemia management and increasing ESA responsiveness in CKD? What medical problems do participants have when taking probiotic? Researchers will compare Erythropoietin only with Erythropoietin + Probiotic to see if Probiotic aids in treating anaemic chronic kidney disease patients. Participants will: Take Erythropoietin + Probiotic or Probiotic only every day for 3 months Visit the clinic once every 4 weeks for checkups and tests Keep a diary of their symptoms
Trial Details
NCT Number NCT07296146
Lead Sponsor Badr University
Conditions Anaemia, Chronic Kidney Disease, Regular Hemodialysis
Enrollment 80 participants
Start Date 2025-12-15
Primary Completion 2026-03-15 (estimated)
Study Completion 2026-05-15 (estimated)
Updated on ClinicalTrials.gov 2025-12-22